Dyne Therapeutics Inc (DYN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.13B
Last updated: Nov 17, 2026 at 4:15 PM ET
Dyne Therapeutics Inc (DYN) Statistics
Dyne Therapeutics (DYN) has a market cap of $3.13B and an enterprise value of $2.43B. Its share count is up 28.17% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 22.36% below the market cap, as cash exceeds debt.
| Market Cap | $3.13B |
|---|---|
| Enterprise Value | $2.43B |
| Latest price (Nov 17, 2026) | $16.02 |
Key Dates
The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 1, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 14.74% over 52 weeks and trades 4.19% below its 50-day average.
| Beta (1Y) | 1.80 |
|---|---|
| 52-Week Change | -14.74% |
| 1-Month Change | +5.19% |
| 3-Month Change | -40.18% |
| 6-Month Change | +0.63% |
| 5-Year Change | +15.02% |
| Total Return (1Y) | -14.74% |
| Total Return (3Y CAGR) | +13.28% |
| Total Return (5Y CAGR) | +0.08% |
| Return vs SPY (1Y) | -35.13% |
| Max Drawdown (1Y) | -46.79% |
| Max Drawdown (3Y) | -85.52% |
| Sharpe Ratio (1Y) | -0.42 |
| Correlation with SPY (1Y) | 0.39 |
| 50-Day Average | $16.72 |
| 200-Day Average | $19.30 |
| 52-Week Range | $14.00 to $27.30 |
| RSI (14 Days) | 41.9 |
| Average Volume (20 Days) | 2.34M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 12.99x current liabilities, and total debt is 0.23x shareholder equity.
| Current Ratio | 12.99x |
|---|---|
| Quick Ratio | 12.99x |
| Debt / Equity | 0.23x |
| Interest Coverage | -34.61x |
Returns and Efficiency
Return on invested capital is -42.87% over the last 12 months, against a 5-year average of -32.67%.
| Return on Equity (ROE) | -64.98% |
|---|---|
| Return on Assets (ROA) | -48.99% |
| Return on Invested Capital (ROIC) | -42.87% |
| ROE (5Y Average) | -92.38% |
| ROA (5Y Average) | -63.28% |
| ROIC (5Y Average) | -32.67% |
Scores
DYN has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$521.00K |
| Operating Income | -$620.14M |
| Pretax Income | -$604.92M |
| Net Income | -$604.92M |
| Reported EPS (TTM) | -$3.60 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 75.69% of the $1.23B in total assets.
| Cash and Equivalents | $913.20M |
|---|---|
| Total Debt | $213.32M |
| Net Cash | $699.88M |
| Net Cash Per Share | $3.85 |
| Working Capital | $1.09B |
| Shareholder Equity | $930.93M |
| Book Value Per Share | $5.12 |
| Total Assets | $1.23B |
| Total Liabilities | $303.87M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $4.23M of capital spending, operating cash flow left -$568.76M of free cash flow.
| Operating Cash Flow | -$564.53M |
|---|---|
| Capital Expenditures | $4.23M |
| Free Cash Flow | -$568.76M |
| FCF Per Share | -$3.05 |
| Depreciation and Amortization | $2.89M |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | +125.61% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | +125.61% |
Dividends and Yields
DYN does not pay a dividend. Its free cash flow yield is -19.53%.
| FCF Yield | -19.53% |
|---|---|
| Buyback Yield | -26.88% |
| Shareholder Yield | -26.88% |
Peer Position
Against 4 similar companies, DYN has the 4th highest ROIC.
ROICPeer median -34.87%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -82.99%
| ROIC | -42.87% vs -34.87% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -100.00% vs -82.99% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About DYN
What is DYN's market cap?
Dyne Therapeutics has a market cap of $3.13B. Its enterprise value, which adds debt and subtracts cash, is $2.43B.
How many shares of DYN are outstanding?
Dyne Therapeutics has 181.77M shares outstanding. The count is up 28.17% from a year earlier.
Does DYN pay a dividend?
No. Dyne Therapeutics does not pay a dividend.
How much debt does DYN have?
Dyne Therapeutics has $213.32M of total debt and $913.20M of cash and equivalents, a net cash position of $699.88M.
DYN pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors